Triptorelin Market In-Depth Industry Analysis on Ipsen, Bachem, Ferring Pharmaceuticals Pvt Ltd., Chengdu Tiantaishan pharmaceutical Co., Ltd., Tecnofarma

Gonadotropin-releasing hormone (GnRH) agonists are more effective and safe compared to estrogens and anti-androgens used to attain medical castration. GnRH agonists offer slow-release formulations that aids in enhancing quality of life of patients and reducing related expenditures. It is more likely that prostate cancer progresses with increasing testosterone hormone. It is often recommended to remove testicles or use medication therapy to halt the production of testosterone. Triptorelin is GnRH agonists that can halt the production of testosterone, which decreases the level of testosterone, thereby restricting the development of prostate cancer.

Triptorelin can also be effective in the treatment of Central Precocious Puberty (CPP) in children two years of age or above. Increasing approval and launch of novel products is expected to boost growth of the market. For instance, in July 2017, the U.S. Food and Drug Administration (FDA) approved Arbor Pharmaceuticals’: Triptodur for the treatment of central precocious puberty in pediatric patients. The approval was given on the grounds of a phase 3 clinical trial (Efficacy, Safety, and Pharmacokinetics [PK] of Triptorelin 6-month Formulation in Patients with Central Precocious Puberty) that evaluated prepubertal luteinizing hormone levels using triporelin therapy. Use of Triptodur led to increase in pre-pubertal luteinizing hormone (LH) levels by 93% in the participants and the pre-pubertal luteinizing hormone (LH) suppression was maintained at 12 months by 98% of patients.

Get Request Sample from Industry Experts @ https://www.coherentmarketinsights.com/insight/request-sample/1963

The global triptorelin market size was valued at US$ 426.4 Mn in 2017, and is expected to witness a CAGR of 5.2% over the forecast period (2018 – 2026).

Triptorelin is a first-line hormonal therapy that can be effective and safe in the treatment of non-metastatic or metastatic prostate cancer. Increasing R&D has also been done to evaluate the efficacy of triptorelin in treatment of various diseases. For instance, in May 2018, Immune System Regulation AB began a study to assess the efficacy of triptorelin in HIV-1 reservoir reduction in Antiretroviral Therapy (ART) treated HIV-1 infected patients and the study is currently in phase II clinical stage. Moreover, in July 2017, National Cancer Institute (NCI), Naples sponsored a study to assess the efficacy and safety of Tamoxifen, Letrozole and Letrozole + Zoledronate in the treatment of bone loss in breast cancer patients and the study is currently in phase III clinical stage. Successful completion of these trials and subsequent launch of these therapies is expected to boost growth of the market during the forecast period.

Triptorelin is highly effective in the suppression of gonadotropin in Central Precocious Puberty (CPP) in children, which further increases its demand. For instance, according to data published in the Scientific World Journal, in May 2012, triptorelin 11.25 mg per 90 days efficiently suppressed the pituitary-gonadal level in children with CPP from first administration.

Get PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1963

Key players in the market are focused on R&D in androgen deprivation therapy with triptorelin to decrease development of salivary gland cancer expressing androgen receptors. For instance, in January 2016, Debiopharm International SA collaborated with European Organization for Research and Treatment of Cancer (EORTC) to investigate Triptorelin for the treatment of salivary gland cancer. Under the collaboration, Debiopharm International SA will supply triptorelin pamoate 3.75 mg 1-month formulation to patients suffering from salivary gland cancer participating in a clinical study sponsored by EORTC. During the clinical study, researchers are expected to assess the efficacy and safety of androgen chemotherapy versusandrogen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptors-expressing salivary gland cancers.

Moreover, according to the Cancer Research U.K., in 2015, around 47,151 new cases of prostate cancer were registered in the U.K. Furthermore, prostate cancer accounted for 13% of the total cancer cases in the U.K., in 2015. Prostate cancer is the second-most common cause of cancer deaths among males in the U.K. in 2014, accounting for 13% of all cancer deaths among males. According to the same source, in 2014, around 11,287 prostate cancer deaths were recorded among males in the U.K. The crude mortality rate shows that there were 36 prostate cancer deaths for every 100,000 males in the country.

Key players operating in triptorelin market include, Chengdu Tiantaishan Pharmaceutical Co., Ltd., Tecnofarma, Ipsen, Bachem, Ferring Pharmaceuticals Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Debiopharm Group, Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.), and Arbor Pharmaceuticals, LLC.

Inquire about Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/1963

Contact Us:

Name: Mr. Raj Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.